China
Africa
Explore chapters and articles related to this topic
Nanomaterial-Antibody Hybrids
Published in Feng Chen, Weibo Cai, Hybrid Nanomaterials, 2017
Jyothi U. Menon, Lei Song, Nadia Falzone, Katherine A. Vallis
Doxorubicin has also been used in the treatment of mesangial cellmediated nephropathy, by targeting the Thy1.1 antigen (OX7) in a rat model (Tuffin et al. 2005). F(ab′)2-fragments of the OX7 mAb were coupled to doxorubicin-encapsulated immunoliposomes. Marked uptake in mesangial cell cytoplasm was noted after a single intravenous (i.v.) injection that lead to extensive glomerular damage with little effect on the normal kidney. The same target-antigen strategy was employed to deliver mycophenolate mofetil (MMF)-containing immunoliposomes in a rat model (Suana et al. 2011). Administration of MMF-loaded OX7-IL resulted in a reduction of mesangial cells and glomerular extracellular matrix expansion (a feature of nephropathy). These immunoliposomes therefore offer a promising delivery system in the treatment of mesangial cell mediated glomerulonephritis. Another biomarker, CD74 (a type II transmembrane protein expressed on B cells and upregulated in lymphocytic leukaemia), has also been investigated for active immunoliposome drug delivery. An anti-CD74 antibody (milatuzumab) was incorporated into liposomes designed as targeted dexamethasone carriers and was found to increase drug bioavailability and cytotoxicity in comparison to free drug in CD74+ lymphoma cells (Mao et al. 2013).
A new one-dimensional copper(II) coordination polymer: crystal structure and treatment activity on diabetic nephropathy
Published in Inorganic and Nano-Metal Chemistry, 2021
Pan-Pan Lin, Qiao-Ling Xie, Ling-Wei Chen
Studies have shown that continuous hyperglycemia stimulation can cause human glomerular mesangial cells to secrete inflammatory factors, such as serum amyloid A, tumor necrosis factor-α (TNF-α) and fibronectin expression, and increase renal interstitial fibrosis. So, the ELISA detection was conducted and the content of the serum amyloid A and TNF-α was determined. The results in Figure 4 showed that the there was a significantly increased levels of the serum amyloid A and TNF-α in the model group, which was much higher than the control group. Under the treatment of the new compound, the serum amyloid A and TNF-α content was significantly reduced. The inhibition of the compound also showed a dose related manner.